FDA — authorised 17 December 1985
- Application: NDA019422
- Marketing authorisation holder: XTTRIUM
- Status: supplemented
FDA authorised Antimicrobial on 17 December 1985 · 158 US adverse-event reports
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Yes. FDA authorised it on 17 December 1985; FDA has authorised it.
XTTRIUM holds the US marketing authorisation.